Eli Lilly and Company $LLY Shares Sold by Zevin Asset Management LLC

Zevin Asset Management LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 3.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,131 shares of the company’s stock after selling 404 shares during the period. Zevin Asset Management LLC’s holdings in Eli Lilly and Company were worth $9,456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Lazard Freres Gestion S.A.S. grew its stake in shares of Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after buying an additional 41,222 shares in the last quarter. Precedent Wealth Partners LLC increased its stake in Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after buying an additional 39 shares during the period. Capital Advisors Inc. OK lifted its holdings in Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after buying an additional 429 shares in the last quarter. Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the second quarter worth $54,000. Finally, Duquesne Family Office LLC raised its stake in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after acquiring an additional 32,640 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on LLY shares. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Cantor Fitzgerald increased their price objective on Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a report on Friday, October 31st. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Berenberg Bank reiterated a “hold” rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $950.00.

Eli Lilly and Company Stock Down 1.3%

Shares of LLY opened at $924.80 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $955.46. The company’s fifty day moving average is $796.15 and its two-hundred day moving average is $775.03. The firm has a market cap of $874.29 billion, a PE ratio of 60.52, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the company posted $1.18 EPS. The business’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 4,314 shares of company stock worth $2,766,929 over the last 90 days. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.